|
Match
|
Document |
Document Title |
|
|
US20110177092 |
INDIVIDUAL 5-FLUOROURACILE DOSE OPTIMIZATION IN FOLFIRI TREATMENT
The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by... |
|
|
US20110076317 |
Rapid establishment and/or termination of substantial steady-state drug delivery
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative... |
|
|
US20110014206 |
SCREENING METHOD FOR PREDICTING SUSCEPTIBILITY TO BREAST CANCER
A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least... |
|
|
US20140286961 |
Novel Methods Of Cancer Therapy Targeted Against A Cancer Stem Line
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous... |
|
|
US20110250201 |
ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of... |
|
|
US20140248211 |
METHOD OF TREATING CANCER
The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and... |
|
|
US20120141376 |
PROSTATE SPECIFIC TRANSCRIPTS AND THE USE THEREOF FOR PROSTATE CANCER THERAPEUTICS AND DIAGNOSTICS
Genes that are up regulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment,... |
|
|
US20140348854 |
HE4 Based Therapy For Malignant Disease
The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases. |
|
|
US20140161813 |
METHODS FOR THE DIAGNOSIS, TREATMENT AND MONITORING OF CANCER
New methods for diagnosing, treating, and monitoring cancer have been developed based on the expression level of markers, such as transcobalamin II (TCII), transcobalamin II receptor (TCIIR),... |
|
|
US20110300131 |
DETECTION AND TREATMENT OF PANCREATIC, OVARIAN AND OTHER CANCERS
The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70. |
|
|
US20140134165 |
Identification of Tumor-Associated Markers for Diagnosis and Therapy
The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which... |
|
|
US20130189225 |
METHODS OF INCREASING EFFICIENCY OF VECTOR PENETRATION OF TARGET TISSUE
Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the... |
|
|
US20130028860 |
ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE AND/OR FEVER
The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for... |
|
|
US20110182909 |
Glufosfamide combination therapy
Glufosfamide administered in combination with other chemotherapeutic agents is useful in cancer treatment. |
|
|
US20120128586 |
METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface... |
|
|
US20120141475 |
TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody.... |
|
|
US20120070438 |
Methods for Treating Melanoma
Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in... |
|
|
US20120276192 |
COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1
RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory... |
|
|
US20070009535 |
Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to... |
|
|
US20150093396 |
Prostate Tumor Markers And Methods Of Use Thereof
Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as... |
|
|
US20110287020 |
RECOMBINANT VECTORS
This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in... |
|
|
US20100297118 |
Therapeutic Cancer Treatments
Provided are methods for treating non-small cell lung cancer by administering a therapeutically effective amount of a hedgehog inhibitor. |
|
|
US20100209944 |
ADAMTS-7 AS A BIOMARKER FOR CANCERS OF EPITHELIAL ORIGIN
ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial... |
|
|
US20060210572 |
Treatment of lymphatic metastatic cancerous lesions
Methods for improving the efficacy of cancer therapy are described. In one embodiment the method involves administering the cancer therapeutic to a first cancer lesion wherein the first cancer... |
|
|
US20120195830 |
Monoclonal Antibodies Against Claudin-18 For Treatment of Cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric... |
|
|
US20110020430 |
Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
Methods for treating neuroblastoma in a subject are provided. The methods include administering to the subject nucleic acid that is capable of causing a significant reduction of the amount of... |
|
|
US20060115424 |
Combination therapy of oxaliplatin and radioactively doped particles treating cancer
A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies... |
|
|
US20050158325 |
Immunomodulatory combinations
The present invention provides immunomodulatory combinations that includes an IRM component and a therapeutic agent, each in an amount that, when in combination with the other, is effective for... |
|
|
US20130315896 |
Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the... |
|
|
US20120020880 |
Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the... |
|
|
US20120076724 |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate... |
|
|
US20140335100 |
THERAPY-ENHANCING GLUCAN
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a... |
|
|
US20110195071 |
THERAPY-ENHANCING GLUCAN
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a... |
|
|
US20070160619 |
CTLA-4 Antibody Dosage Escalation Regimens
A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response... |
|
|
US20070009532 |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such... |
|
|
US20060159689 |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of... |
|
|
US20070104721 |
Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
A combination of temsirolimus and herceptin in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of herceptin and HKI-272 is also provided.... |
|
|
US20070128201 |
Combined use of ecteinascidin-743 and platinum antineoplastic compounds
ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient. |
|
|
US20050031622 |
Treatment and diagnosis of cancer using inositolphosphoglycans antagonists
Inositolphosphoglycans (IPGs), and in particular A-type substances comprising myo-inositol, are tumour autocrine factors (TAFs), that is factors which cause tumour cell proliferation. The use of... |
|
|
US20070071762 |
COMPREHENSIVE DIAGNOSTIC TESTING PROCEDURES FOR PERSONALIZED ANTICANCER CHEMOTHERAPY (PAC)
The present invention provides methods of assessing and selecting treatment modalities for cancer. |
|
|
US20080050730 |
Early Detection of Hemangiosarcoma and Angiosarcoma
A variety of methods, compositions and kits are provided for the early detection, diagnosis and treatment of hemangiosarcoma in dogs and angiosarcomas in humans. |
|
|
US20090060913 |
COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES
The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly... |
|
|
US20110171229 |
MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA
It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC),... |
|
|
US20060110396 |
Use of ligands of the antigen CDw52 for the treatment of diseases that are related to degenerated macrophages
The present invention relates to the use of a ligand of CDw52 for the preparation of a medicament for the treatment of diseases that are related to CDw52 expressing degenerated macrophages. In... |
|
|
US20110256147 |
DIAGNOSTIC AND TREATMENT METHODS FOR CANCER BASED ON IMMUNE INHIBITORS
Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the... |
|
|
US20110250166 |
COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER
The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising... |
|
|
US20110229552 |
NOVEL mRNA SPLICE VARIANT OF THE DOUBLECORTIN-LIKE KINASE GENE AND ITS USE IN DIAGNOSIS AND THERAPY OF CANCERS OF NEUROECTODERMAL ORIGIN
The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis. |
|
|
US20050118658 |
Use of ERRalpha phosphorylation status as a breast cancer biomarker
The inventors discovered that the ErbB2 signal transduction pathway can activate ERRĪ± by inducing its phosphorylation. Based on this discovery, the present invention provides methods for... |
|
|
US20070003559 |
METHODS OF DETERMINING PHARMACOKINETICS OF TARGETED THERAPIES
Methods for determining pharmacokinetics of targeted therapies. |
|
|
US20070032457 |
Combination therapy for cancer treatment
The present invention provides methods of treating cancer, the methods generally involving combination therapy. The methods are useful as primary cancer therapy, or as adjuvant therapy. The... |